Sluggish Parexel could be poised for a long-term turnaround

Parexel International ($PRXL) startled investors last quarter when its net new business dropped 30% from the previous three months. But, as The Motley Fool points out, the CRO giant is well-positioned in a growing industry, and sales are likely to rebound. Article

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.